Lumida
/FHTX
⌘K
Foghorn Therapeutics Inc

Foghorn Therapeutics Inc

FHTX
$4.42USD-1.56%-0.07 today

MARKET CAP

262.5M

P/E (TTM)

FWD P/E

DAY RANGE

$4 – $5

52W RANGE

$3
$8

AI Summary

Stalk
TrimMedium

FHTX remains in a prolonged Stage 4 decline under sustained lower highs and lower lows with EMAs sloping downward and acting as resistance. The active Bearish Exhaustion pattern signals sellers losing control and increases the probability of a bottoming attempt or reversal bounce. Despite extreme oversold readings, lack of sustained reversal suggests selling is best deferred. Favor trimming on rallies into declining EMA regions or prior support-turned-resistance zones for structurally aligned execution.

  • Q2 collaboration revenue rose to $16.1M from $7.6M last year.
  • Net loss shrank to $7.2M from $17.9M as R&D expenses fell to $18.5M.
  • Profitability remains weak, failing to convert revenue into profit.
Full analysis →
Insider Trades8 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Apr 9, 2026SellFHTXAdrian GottschalkChief Executive Officer213,410$4.79$262.5M-41.92%+35.17%$1.0M+0.00%Trim
Apr 25, 2025SellFHTXAdrian GottschalkChief Executive Officer600,000$4.36$262.5M-41.92%+35.17%$2.6M+0.00%Trim
Apr 9, 2025SellFHTXAdrian GottschalkChief Executive Officer395,812$3.54$262.5M-41.92%+35.17%$1.4M+0.00%Trim
Sep 20, 2024SellFHTXCarlos CostaChief People Officer73,226$6.88$262.5M-41.92%+35.17%$503.9K+0.00%10b5-1Trim
Sep 18, 2024SellFHTXCarlos CostaChief People Officer23,148$6.89$262.5M-41.92%+35.17%$159.4K+0.00%10b5-1Trim
Sep 16, 2024SellFHTXCarlos CostaChief People Officer21,344$6.88$262.5M-41.92%+35.17%$146.8K+0.00%10b5-1Trim
Sep 9, 2024SellFHTXSteven F. BellonChief Scientific Officer20,000$9.50$262.5M-41.92%+35.17%$190.0K-16.40%10b5-1Trim
Mar 11, 2024SellFHTXFanny CavalieChief Strategy/Bus Ops Officer11,000$6.56$262.5M-41.92%+35.17%$72.1K-12.64%Trim